Your browser doesn't support javascript.
loading
Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype.
Mallo, Mar; Tuechler, Heinz; Arenillas, Leonor; Raynaud, Sophie; Cluzeau, Thomas; Shih, Lee-Yung; Tung-Liang, Chiang; Ganster, Christina; Shirneshan, Katayoon; Haase, Detlef; Mascaró, Martí; Palomo, Laura; Cervera, José; Such, Esperanza; Trim, Nicola; Jeffries, Sally; Ridgway, Emma; Marconi, Giovanni; Martinelli, Giovanni; Solé, Francesc.
Afiliación
  • Mallo M; MDS Research Group Institut de Recerca Contra la Leucèmia Josep Carreras (IJC) ICO-Hospital Germans Trias i Pujol Universitat Autònoma de Barcelona Badalona Spain.
  • Tuechler H; Microarrays Unit Institut de Recerca Contra la Leucèmia Josep Carreras (IJC) ICO-Hospital Germans Trias i Pujol Universitat Autònoma de Barcelona Badalona Spain.
  • Arenillas L; Boltzmann Institute for Leukaemia Research and Hematology Vienna Austria.
  • Raynaud S; Hematological Cytology Laboratory Pathology Department Hospital del Mar GRETNHE, IMIM (Hospital del Mar Research Institute) Barcelona Spain.
  • Cluzeau T; Hematology Department Cote d'Azur University CHU of Nice Nice France.
  • Shih LY; Hematology Department Cote d'Azur University CHU of Nice Nice France.
  • Tung-Liang C; Division of Hematology Chang Gung Memorial Hospital-Linkuo Chang Gung University Taoyuan City Taiwan.
  • Ganster C; Division of Hematology Chang Gung Memorial Hospital-Linkuo Chang Gung University Taoyuan City Taiwan.
  • Shirneshan K; Clinics of Hematology and Medical Oncology University Medical Center Göttingen Göttingen Germany.
  • Haase D; Clinics of Hematology and Medical Oncology University Medical Center Göttingen Göttingen Germany.
  • Mascaró M; Clinics of Hematology and Medical Oncology University Medical Center Göttingen Göttingen Germany.
  • Palomo L; Hematology Service Hospital Son Llàtzer Palma de Mallorca Spain.
  • Cervera J; Experimental Hematology Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona Spain.
  • Such E; Hematology Service Hospital Universitario La Fe Valencia Spain.
  • Trim N; Hematology Service Hospital Universitario La Fe Valencia Spain.
  • Jeffries S; West Midlands Regional Genetics Laboratory Birmingham Women's Hospital Birmingham UK.
  • Ridgway E; West Midlands Regional Genetics Laboratory Birmingham Women's Hospital Birmingham UK.
  • Marconi G; West Midlands Regional Genetics Laboratory Birmingham Women's Hospital Birmingham UK.
  • Martinelli G; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" Meldola Italy.
  • Solé F; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" Meldola Italy.
EJHaem ; 4(2): 446-449, 2023 May.
Article en En | MEDLINE | ID: mdl-37206269
ABSTRACT
Half of the myelodysplastic syndromes (MDS) have normal karyotype by conventional banding analysis. The percentage of true normal karyotype cases can be reduced by 20-30% with the complementary application of genomic microarrays. We here present a multicenter collaborative study of 163 MDS cases with a normal karyotype (≥10 metaphases) at diagnosis. All cases were analyzed with the ThermoFisher® microarray (either SNP 6.0 or CytoScan HD) for the identification of both copy number alteration(CNA) and regions of homozygosity (ROH). Our series supports that 25 Mb cut-off as having the most prognostic impact, even after adjustment by IPSS-R. This study highlights the importance of microarrays in MDS patients, to detect CNAs and especially to detect acquired ROH which has demonstrated a high prognostic impact.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: EJHaem Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: EJHaem Año: 2023 Tipo del documento: Article